Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367696 | 0.85 | PTGS2 (0.39) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL21682593 | 0.83 | PTGS2 (0.36) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL21682594 | 0.82 | PTGS2 (0.38) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL1243878 | 0.81 | PTGS2 (0.38) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL12889839 | 0.77 | PTGS2 (0.38) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL12889838 | 0.77 | PTGS2 (0.38) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL12889841 | 0.77 | PTGS2 (0.38) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL12889840 | 0.77 | PTGS2 (0.38) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL1244557 | 0.77 | PTGS2 (0.36) | PTGS2PTGS1 | |
| SCHEMBL1244559 | 0.77 | PTGS2 (0.36) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622501-B2 | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2009-11-24 | — | — | US | disclosed |
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
| EP-1711459-A4 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2008-01-02 | — | — | EP | disclosed |
| EP-1711459-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Company (CA) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070883-A1 | NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST COMPANY (CA) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242643-A1 | Nitric Oxide Releasing Prodrugs of Diaryl-2-(5H)-Furanones as Cyclooxygenase-2 Inhibitors | PTGIS, PTGS1, PTGS2 | PTGS2 3/4885PTGS1 2/4885CA1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.